Published in Clin Cancer Res on December 15, 2008
Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One (2010) 3.96
The NF90-NF45 complex functions as a negative regulator in the microRNA processing pathway. Mol Cell Biol (2009) 1.71
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer (2010) 1.54
The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. Int J Oncol (2013) 1.25
Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One (2010) 1.17
Multi-walled carbon nanotube-induced gene expression in the mouse lung: association with lung pathology. Toxicol Appl Pharmacol (2011) 1.13
The structure, function and evolution of proteins that bind DNA and RNA. Nat Rev Mol Cell Biol (2014) 1.10
Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One (2012) 1.06
Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin. Mol Cell Proteomics (2012) 1.02
Multiwalled carbon nanotube-induced gene signatures in the mouse lung: potential predictive value for human lung cancer risk and prognosis. J Toxicol Environ Health A (2012) 1.01
Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression. Oncogene (2012) 1.00
New perspectives for in vitro risk assessment of multiwalled carbon nanotubes: application of coculture and bioinformatics. J Toxicol Environ Health B Crit Rev (2012) 0.88
Highlight report: Validation of prognostic genes in lung cancer. EXCLI J (2014) 0.86
A robust tool for discriminative analysis and feature selection in paired samples impacts the identification of the genes essential for reprogramming lung tissue to adenocarcinoma. BMC Genomics (2011) 0.86
Novel image markers for non-small cell lung cancer classification and survival prediction. BMC Bioinformatics (2014) 0.86
Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy. PLoS One (2013) 0.85
Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics. J Transl Med (2015) 0.85
A novel five gene signature derived from stem-like side population cells predicts overall and recurrence-free survival in NSCLC. PLoS One (2012) 0.85
NF90 in posttranscriptional gene regulation and microRNA biogenesis. Int J Mol Sci (2013) 0.85
Systematic analysis of multiwalled carbon nanotube-induced cellular signaling and gene expression in human small airway epithelial cells. Toxicol Sci (2013) 0.84
The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts. Cancer Epidemiol Biomarkers Prev (2014) 0.84
Prognostic value of microRNA expression in operable non-small cell lung cancer patients. Br J Cancer (2014) 0.84
Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study. PLoS One (2011) 0.84
Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer. PLoS One (2014) 0.83
Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for lung cancer: A marker phase I trial. Thorac Cancer (2014) 0.82
Cancer research: from prognostic genes to therapeutic targets. EXCLI J (2014) 0.81
Overexpression of NF90-NF45 Represses Myogenic MicroRNA Biogenesis, Resulting in Development of Skeletal Muscle Atrophy and Centronuclear Muscle Fibers. Mol Cell Biol (2015) 0.81
Colorectal cancer derived organotypic spheroids maintain essential tissue characteristics but adapt their metabolism in culture. Proteome Sci (2014) 0.81
Integrated DNA Copy Number and Gene Expression Regulatory Network Analysis of Non-small Cell Lung Cancer Metastasis. Cancer Inform (2014) 0.80
MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating nuclear factor 90/vascular endothelial growth factor A axis. Cell Death Dis (2016) 0.79
Upregulated expression of ILF2 in non-small cell lung cancer is associated with tumor cell proliferation and poor prognosis. J Mol Histol (2015) 0.79
Forfeited hepatogenesis program and increased embryonic stem cell traits in young hepatocellular carcinoma (HCC) comparing to elderly HCC. BMC Genomics (2013) 0.79
Is there clinical value to prognostic signatures in early-stage NSCLC? Clin Cancer Res (2014) 0.78
Suppression of MicroRNA-7 (miR-7) Biogenesis by Nuclear Factor 90-Nuclear Factor 45 Complex (NF90-NF45) Controls Cell Proliferation in Hepatocellular Carcinoma. J Biol Chem (2016) 0.78
Tal2 expression is induced by all-trans retinoic acid in P19 cells prior to acquisition of neural fate. Sci Rep (2014) 0.77
Reinventing diagnostics for personalized therapy in oncology. Cancers (Basel) (2010) 0.77
High Energy Particle Radiation-associated Oncogenic Transformation in Normal Mice: Insight into the Connection between Activation of Oncotargets and Oncogene Addiction. Sci Rep (2016) 0.75
The T-cell oncogene Tal2 Is a Target of PU.1 and upregulated during osteoclastogenesis. PLoS One (2013) 0.75
Novel interactions between the HTLV antisense proteins HBZ and APH-2 and the NFAR protein family: Implications for the HTLV lifecycles. Virology (2016) 0.75
Lung Cancer Gene Signatures and Clinical Perspectives. Microarrays (Basel) (2013) 0.75
From Proteomic Analysis to Potential Therapeutic Targets: Functional Profile of Two Lung Cancer Cell Lines, A549 and SW900, Widely Studied in Pre-Clinical Research. PLoS One (2016) 0.75
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Serial analysis of gene expression. Science (1995) 60.15
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (2001) 17.36
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Analyzing high-density oligonucleotide gene expression array data. J Cell Biochem (2000) 16.73
A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med (2007) 10.47
MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol (2003) 8.66
Systems biology and new technologies enable predictive and preventative medicine. Science (2004) 7.59
Multidisciplinary management of lung cancer. N Engl J Med (2004) 7.13
Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res (2001) 6.78
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat (2006) 4.42
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Lung cancer. Lancet (2000) 3.93
Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res (2002) 3.68
Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol (2006) 3.53
Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol (2003) 2.45
Validation of array-based gene expression profiles by real-time (kinetic) RT-PCR. J Mol Diagn (2001) 2.40
Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J Clin Oncol (2005) 1.86
Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res (2007) 1.80
Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res (2006) 1.55
Cancer biomarkers--an invitation to the table. Science (2006) 1.53
Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene (2004) 1.41
Cross platform microarray analysis for robust identification of differentially expressed genes. BMC Bioinformatics (2007) 1.39
Cdc42 regulates arsenic-induced NADPH oxidase activation and cell migration through actin filament reorganization. J Biol Chem (2004) 1.15
Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol (2006) 1.12
Identification of candidate maternal-effect genes through comparison of multiple microarray data sets. Mamm Genome (2006) 0.88
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. Am J Physiol Lung Cell Mol Physiol (2005) 7.28
Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol (2005) 6.04
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab (2007) 4.75
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation (2002) 4.02
Exposure to carbon nanotube material: aerosol release during the handling of unrefined single-walled carbon nanotube material. J Toxicol Environ Health A (2004) 3.96
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Mouse pulmonary dose- and time course-responses induced by exposure to multi-walled carbon nanotubes. Toxicology (2009) 3.52
Complete genome sequence of citrus huanglongbing bacterium, 'Candidatus Liberibacter asiaticus' obtained through metagenomics. Mol Plant Microbe Interact (2009) 3.33
Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation (2004) 3.12
MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res (2009) 3.05
Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environ Health A (2003) 2.82
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res (2009) 2.63
Evaluating the toxicity of airborne particulate matter and nanoparticles by measuring oxidative stress potential--a workshop report and consensus statement. Inhal Toxicol (2008) 2.53
Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol (2003) 2.53
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Systemic microvascular dysfunction and inflammation after pulmonary particulate matter exposure. Environ Health Perspect (2006) 2.38
Structure/function implications in a dynamic complex of the intrinsically disordered Sic1 with the Cdc4 subunit of an SCF ubiquitin ligase. Structure (2010) 2.33
Uncovering early response of gene regulatory networks in ESCs by systematic induction of transcription factors. Cell Stem Cell (2009) 2.32
PyK2 and FAK connections to p190Rho guanine nucleotide exchange factor regulate RhoA activity, focal adhesion formation, and cell motility. J Cell Biol (2008) 2.31
Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med (2013) 2.30
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26
Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation (2002) 2.09
Pulmonary fibrotic response to aspiration of multi-walled carbon nanotubes. Part Fibre Toxicol (2011) 2.08
Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem (2004) 2.07
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood (2009) 2.07
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene (2005) 2.07
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. J Clin Oncol (2013) 2.07
Distribution and persistence of pleural penetrations by multi-walled carbon nanotubes. Part Fibre Toxicol (2010) 2.05
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res (2002) 2.05
A novel tool to assess systolic asynchrony and identify responders of cardiac resynchronization therapy by tissue synchronization imaging. J Am Coll Cardiol (2005) 2.03
Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res (2011) 2.03
Dynamic equilibrium engagement of a polyvalent ligand with a single-site receptor. Proc Natl Acad Sci U S A (2008) 2.00
KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. J Thorac Oncol (2014) 1.99
Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood (2010) 1.98
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95
Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology (2010) 1.93
Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun (2003) 1.91
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res (2004) 1.91
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.87
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res (2007) 1.85
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol (2004) 1.85
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun (2003) 1.82
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol (2008) 1.79
Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med (2013) 1.79
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol (2003) 1.79
Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J Toxicol Environ Health B Crit Rev (2008) 1.79
Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity. J Biol Chem (2006) 1.78
Quantitative techniques for assessing and controlling the dispersion and biological effects of multiwalled carbon nanotubes in mammalian tissue culture cells. ACS Nano (2010) 1.78
Particulate matter exposure impairs systemic microvascular endothelium-dependent dilation. Environ Health Perspect (2004) 1.77
Decreased dissolution of ZnO by iron doping yields nanoparticles with reduced toxicity in the rodent lung and zebrafish embryos. ACS Nano (2011) 1.75
Transcriptome analysis of mouse stem cells and early embryos. PLoS Biol (2003) 1.75
Surface area of particle administered versus mass in determining the pulmonary toxicity of ultrafine and fine carbon black: comparison to ultrafine titanium dioxide. Part Fibre Toxicol (2009) 1.74
Dispersal state of multiwalled carbon nanotubes elicits profibrogenic cellular responses that correlate with fibrogenesis biomarkers and fibrosis in the murine lung. ACS Nano (2011) 1.74
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73
Acute pulmonary dose-responses to inhaled multi-walled carbon nanotubes. Nanotoxicology (2012) 1.70
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.69
Influenza-associated mortality in temperate and subtropical Chinese cities, 2003-2008. Bull World Health Organ (2012) 1.69
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res (2002) 1.67
Direct interaction of focal adhesion kinase with p190RhoGEF. J Biol Chem (2003) 1.67
Titanium dioxide nanoparticles: a review of current toxicological data. Part Fibre Toxicol (2013) 1.67
RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res (2002) 1.67
Pulmonary response to intratracheal instillation of ultrafine versus fine titanium dioxide: role of particle surface area. Part Fibre Toxicol (2008) 1.66
Molecular mechanisms of arsenic carcinogenesis. Mol Cell Biochem (2004) 1.66
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res (2005) 1.66
Multi-institutional phase I trials of anticancer agents. J Clin Oncol (2008) 1.65
Meeting report: hazard assessment for nanoparticles--report from an interdisciplinary workshop. Environ Health Perspect (2007) 1.64
Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J Natl Cancer Inst (2003) 1.63
Nanoparticles: health effects--pros and cons. Environ Health Perspect (2006) 1.63
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res (2003) 1.62
Concept of assessing nanoparticle hazards considering nanoparticle dosemetric and chemical/biological response metrics. J Toxicol Environ Health A (2010) 1.61
S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apoptosis. J Biol Chem (2006) 1.61
The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res (2002) 1.60
Metal-induced oxidative stress and signal transduction. Free Radic Biol Med (2004) 1.59
In situ-synthesized novel microarray optimized for mouse stem cell and early developmental expression profiling. Genome Res (2003) 1.58
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol (2008) 1.57
Diseases caused by asbestos: mechanisms of injury and disease development. Int Immunopharmacol (2002) 1.57
Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol (2007) 1.56
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol (2009) 1.56
Pulmonary nanoparticle exposure disrupts systemic microvascular nitric oxide signaling. Toxicol Sci (2009) 1.55
Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res (2006) 1.55